Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad200 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, 2023. Verfasst von Tanios S Bekaii-Saab und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen Inc, Merck Sharp & Dohme Corp, Merck & Co., Inc.
Abstract (Originalsprache)
Background
HER2 overexpression/amplification in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) may be associated with resistance to standard-of-care anti-EGFR therapies. Given the lack of comprehensive investigations into this association, we assessed the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes.
Methods
A systematic review of MEDLINE, Embase, and Cochrane Library (2001-2021) identified studies evaluating progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) in HER2-positive vs. HER2-negative patients with RAS WT mCRC who received anti-EGFR treatments and whose HER2 status was known. Meta-analyses of proportions (ORR) and hazard ratios (PFS, OS) were performed using random-effect models with pre-specified sensitivity analyses.
Results
Five high-quality retrospective cohort studies were included in the meta-analyses representing 594 patients with mCRC. All patients received anti-EGFR treatment, either as monotherapy or in combination with chemotherapy. Meta-analysis of PFS demonstrated a 2.84-fold higher risk of death or progression (95% CI, 1.44-5.60) in patients with HER2-positive (vs. HER2-negative) RAS WT mCRC treated with anti-EGFR regimens. The odds of response to anti-EGFR treatment were 2-fold higher in HER2-negative vs. HER2-positive (odds ratio, 1.96 [95% CI, 1.10-3.48]). Differences in OS were not statistically significant. Sensitivity analyses confirmed the robustness of the base-case estimates.
Conclusions
While this study could not account for all confounding factors, in patients with RAS WT mCRC who received anti-EGFR therapy, HER2 overexpression/amplification was associated with worse PFS and ORR and may therefore predict poorer outcomes. HER2 testing is important to inform treatment decisions and could optimize outcomes for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.
- Maple Health Group, LLC, New York, NY, USA.
- Seagen Inc., Bothell, WA, USA.
- Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
ORCID-Profile: Tanios S Bekaii-Saab, John H Strickler
Förderung
- Seagen Inc
- Merck Sharp & Dohme Corp
- Merck & Co., Inc
Zitieren
APA
Bekaii-Saab, T. S., Lach, K., Hsu, L. I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023). Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. The Oncologist. https://doi.org/10.1093/oncolo/oyad200
Vancouver
Bekaii-Saab TS, Lach K, Hsu LI, Siadak M, Stecher M, Ward J, et al. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. The Oncologist. 2023. doi:10.1093/oncolo/oyad200
BibTeX
@article{BekaiiSaab2023,
author = {Bekaii-Saab, Tanios S and Lach, Krzysztof and Hsu, Ling-I and Siadak, Muriel and Stecher, Mike and Ward, James and Beckerman, Rachel and Strickler, John H},
title = {Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad200}
}
EUVIMED